This is a working overview of bioavailability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
In early 2008, Carrier acquired Environmental Market Solutions, Inc. (EMSI), an environmental and green building consulting company based in the United States. The company has received Leadership in Energy and Environmental Design (LEED) certification from the US Green Building Council for its factories in Charlotte, NC, and Huntington, IN (2009), Shanghai, China (2010), and Monterrey, Mexico (2011). In September 2013, Carrier, Otis, and United Technologies Fire and Security were combined into one subsidiary, UTC Building & Industrial Systems. In 2016, Otis was split off, with the remainder becoming UTC Climate, Controls & Security. In January 2016, Carrier announced it would lay off an unspecified number of employees at its research and development division in the town of DeWitt, New York. In February 2016, Carrier announced it would close its Indianapolis factory and move production to Monterrey, Mexico. HVAC Systems and Services North America president Chris Nelson cited "ongoing cost and pricing pressures" and Carrier's "existing infrastructure and a strong supplier base" in Mexico, saying that the move would allow the company "to operate more cost-effectively." The Carrier spokesperson told the crowd that there would be no immediate impact on jobs, that the move would take place over three years, and no jobs would be affected until mid-2017, with the move to be completed by the end of 2019.
An increasingly popular trend is to freeze-dry the animal. For all intents and purposes, a freeze-dried mount is a mummified animal. The internal organs are removed during preparation; however, all other tissue remains in the body. (The skeleton and all accompanying musculature is still beneath the surface of the skin) The animal is positioned into the desired pose, then placed into the chamber of a special freeze-drying machine designed specifically for this application. The machine freezes the animal and also creates a vacuum in the chamber. Pressure in the chamber helps vaporize moisture in the animal's body, allowing it to dry out. The rate of drying depends on vapor pressure. (The higher the pressure, the faster the specimen dries.) Vapor pressure is determined by the temperature of the chamber; the higher the temperature, the higher the vapor pressure is at a given vacuum. The length of the dry-time is important because rapid freezing creates less tissue distortion (i.e.; shrinkage, warping, and wrinkling) The process can be done with reptiles, birds, and small mammals such as cats, rodents, and some dogs. Large specimens may require up to six months in the freeze dryer before they are completely dry. Freeze-drying is the most popular type of pet preservation. This is because it is the least invasive in terms of what is done to the animal's body after death, which is a concern of owners (Most owners do not opt for a traditional skin mount).
Sources: en.wikipedia.org
It disclosed approximately 74,000 families had a child who had been fed melamine-tainted milk, but did not reveal how many of those children had fallen ill as a result. Because of the many months before the scandal was exposed, media suggested the official figures were likely to be understated. Kidney stones in infants started being reported in several parts of China in the two years prior. A number of yet-to-be-officially-acknowledged cases were reported by the media. However, those deaths without an official verdict may be denied compensation. On 1 December 2008 Xinhua reported that the Ministry of Health revised the number of victims to more than 290,000 with 51,900 hospitalized; authorities acknowledged receiving reports of 11 suspected deaths from melamine contaminated powdered milk from provinces, but officially confirmed three deaths. On characterisation and treatment of urinary stones in affected infants, the New England Journal of Medicine printed an editorial in March 2009, along with reports on cases from Beijing, Hong Kong and Taipei. Urinary calculi specimens were collected from 15 cases treated in Beijing and were analysed as unknown objects for their components at Beijing Institute of Microchemistry using infrared spectroscopy, nuclear magnetic resonance, and high-performance liquid chromatography. The result of the analyses showed the calculi were composed of melamine and uric acid, and the molecular ratio of uric acid to melamine was around 2:1.
For example, 5α-pregnane-3α,17α-diol-20-one has a hydrogen atom at the 5α position (hence the "5α-" prefix), two hydroxy groups (-OH) at the 3α and 17α positions (hence "3α,17α-diol" suffix) and an oxo group (=O) at the position 20 (hence the "20-one" suffix). However, erroneous use of suffixes can be found, e.g., "5α-pregnan-17α-diol-3,11,20-trione" [sic] — since it has just one hydroxy group (at 17α) rather than two, then the suffix should be -ol, rather than -diol, so that the correct name to be "5α-pregnan-17α-ol-3,11,20-trione". According to the rule set in the Nomenclature of Steroids, the terminal "e" in the parent structure name should be elided before the vowel (the presence or absence of a number does not affect such elision). This means, for instance, that if the suffix immediately appended to the parent structure name begins with a vowel, the trailing "e" is removed from that name. An example of such removal is "5α-pregnan-17α-ol-3,20-dione", where the last "e" of "pregnane" is dropped due to the vowel ("o") at the beginning of the suffix -ol. Some authors incorrectly use this rule, eliding the terminal "e" where it should be kept, or vice versa. The term "11-oxygenated" refers to the presence of an oxygen atom as an oxo (=O) or hydroxy (-OH) substituent at carbon 11. "Oxygenated" is consistently used within the chemistry of the steroids since the 1950s. Some studies use the term "11-oxyandrogens" as an abbreviation for 11-oxygenated androgens, to emphasize that they all have an oxygen atom attached to carbon at position 11.
Non-essential nutrients are substances within foods that can have a significant impact on health. Dietary fiber is not absorbed in the human digestive tract. Soluble fiber is metabolized to butyrate and other short-chain fatty acids by bacteria residing in the large intestine. Soluble fiber is marketed as serving a prebiotic function with claims for promoting "healthy" intestinal bacteria.
==== Heart attack ==== On 21 June 1993, Heseltine suffered a serious heart attack in Venice (especially worrying as Heseltine was sixty, and his father had died of a heart attack aged fifty-five). The pains had already stopped by the time he reached hospital. Heseltine was shown looking unwell and using a wheelchair – in fact the result of gout in his foot from the medication which he was taking. He took four months off from work, and did not make a speech at the party conference in October 1993, instead amusing the audience by appearing on the platform and performing mock exercises with his arms. There were concerns about his ability to remain in government. In 1994 Chris Morris jokingly implied on BBC Radio 1 that Heseltine had died, and persuaded MP Jerry Hayes to broadcast an on-air tribute. Morris was subsequently suspended.
Sources: en.wikipedia.org
==== Porotic hyperostosis/cribra orbitalia ==== It was long assumed that iron deficiency anemia has marked effects on the flat bones of the cranium of infants and young children. That as the body attempts to compensate for low iron levels by increasing red blood cell production in the young, sieve-like lesions develop in the cranial vaults (termed porotic hyperostosis) and/or the orbits (termed cribra orbitalia). This bone is spongy and soft. It is however, unlikely that iron deficiency anemia is a cause of either porotic hyperostosis or cribra orbitalia. These are more likely the result of vascular activity in these areas and are unlikely to be pathological. The development of cribra orbitalia and porotic hyperostosis could also be attributed to other causes besides a dietary iron deficiency, such as nutrients lost to intestinal parasites. However, dietary deficiencies are the most probable cause. Anemia incidence may be a result of inequalities within society, and/or indicative of different work patterns and activities among different groups within society.
Member American Academy of Arts & Sciences (2025) Member, The World Academy of Science (2025) Founders Award, Controlled Release Society (2025) Distinguished Scientist Award, American Association of Pharmaceutical Scientists (2024) Doing a World of Good Medal (2023) BIOS- Top 50 Lifescience Entrepreneur List (2022) Kydonieus Award, Controlled Release Society (2020) Clemson Award, Society for Biomaterials (2017) Member, National Academy of Medicine (NAM) (2016) Fellow, Biomedical Engineering Society (BMES) (2015) Fellow, American Association of Pharmaceutical Scientists (AAPS) (2015) Fellow, Controlled Release Society (CRS) (2015) Andreas Acrivos Award for Professional Progress, American Institute of Chemical Engineers (AIChE) (2015) Member, National Academy of Engineering (NAE) (2015) Fellow, National Academy of Inventors (NAI) (2013) Fellow, American Association for the Advancement of Science (AAAS) (2012) Fellow, American Institute for Medical and Biological Engineering (AIMBE) (2010) Controlled Release Society’s Young Scientist Award (2008) American Institute of Chemical Engineers Allan P. Colburn award (2005) Selection by MIT's Technology Review Magazine as one of the world's top Innovators Under 35 (1999)
==== Fat ==== Based on the findings that FNDC5 induces thermogenin expression in fat cells, overexpression of FNDC5 in the liver of mice prevents diet-induced weight gain, and FNDC5 mRNA levels are elevated in human muscle samples after exercise, it has been proposed that irisin promotes the conversion of white fat to brown fat in humans, which would make it a health-promoting hormone. While this proposal has been challenged by evidence finding FNDC5 is upregulated only in highly active elderly humans, more recent literature has supported the hypothesis of FNDC5 and irisin having a necessary role in exercise related benefits.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.